Drug Profile
PIM 447
Alternative Names: LGH-447; PIM447Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Novartis
- Developer Novartis; Novartis Oncology
- Class Antineoplastics
- Mechanism of Action Proto oncogene proteins c pim 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Multiple myeloma
- No development reported Acute myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, Second-line therapy or greater) in Australia (PO)
- 28 Jul 2021 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, Second-line therapy or greater) in France (PO)
- 28 Jul 2021 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, Second-line therapy or greater) in Germany (PO)